We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 292

Court orders the production of transcripts from prior unrelated cases because they are relevant to issues in the current action
  • Borden Ladner Gervais LLP
  • Canada
  • December 3 2015

Teva has appealed a Prothonotary's order to provide documents refused to be produced at examination for discovery of the Teva representative. The


Patent claim resulted from “skilled work”, not “creative work”, and is found to be obvious
  • Borden Ladner Gervais LLP
  • Canada
  • December 3 2015

The Federal Court has dismissed an application for prohibition for obviousness. The invention was described as “to take the ‘naturally occurring'


Patent is not found to be a selection patent, and thus was anticipated and obvious
  • Borden Ladner Gervais LLP
  • Canada
  • November 23 2015

The Federal Court has dismissed an application for prohibition to prevent the Minister of Health from issuing an NOC to Mylan for cinacalcet


FCA reinstates PMPRB jurisdiction over generic companies with permission from patentee to sell medicine as they enjoyed a benefit from the patent
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2015

In these cases, the government appealed Federal Court decisions that allowed judicial reviews of multiple PMPRB decisions. The issue on appeal was


Gilead has successfully obtained a declaration of invalidity of a patent that it reasonably expected would be asserted against it
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2015

The Federal Court has allowed Gilead’s claim to invalidate Idenix's '191 patent on the grounds of insufficient disclosure and lack of demonstrated


Data protection regulations apply when comparison added after NDS filed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2015

In this case, Hospira applied for judicial review of a decision of the Minister of Health, refusing to issue it a Notice of Compliance (NOC) for its


Relevance does not necessarily mean a question must be answered on discovery
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2015

In this patent infringement action, the defendants sought to compel answers refused on discovery. The Prothonotary heard the motion and dismissed it


Struck paragraphs claiming section 8 losses relating to overall market share are allowed back into the pleadings
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2015

The Federal Court has allowed an appeal of a Prothonotary's decision that struck out certain paragraphs of an Amended Statement of Claim without


FCA dismisses appeal; upholds finding that obviousness allegations are justified
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2015

The Federal Court of Appeal (FCA) issued two sets of reasons stemming from two appeals between these companies. Both appeals were from the same


Court refuses prohibition order; finds allegations of non-infringement and obviousness justified
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2015

The Federal Court dismissed the proceeding, refusing to grant Lilly a prohibition order in relation to its formulation patent. The Court held that